Literature DB >> 6503212

[Analysis of prognostic factors in plasmacytoma].

W Gassmann, T Haferlach, N Schmitz, W Kayser, H H Euler, J Drews, H Löffler.   

Abstract

For analysis of prognostic factors the clinical course of 109 patients with multiple myeloma was evaluated. Survival curves of immunoglobulin (Ig)G- and IgA-myelomas were identical (Fig. 1) with median survival times of 52 and 42 months, respectively, whereas patients with IgD- and Bence-Jones-myeloma had short survival times (median 3 months). Most important risk factors were anemia, renal insufficiency, and hypercalcemia (Figs. 7 and 8). Median survival time dropped from 52 months (Hb above 100 g/l) to 22 (Hb 85-100 g/l) and 1 month (Hb below 85 g/l). Patients with serum creatinine values below 2 mg/dl lived significantly longer than those with values above. Median survival times were 52 and 1 month, respectively. All seven hypercalcemic patients had a renal insufficiency and were in a very poor condition; their median survival time was 1 month. Analysis of the widely used staging system of Durie and Salmon gave disappointing results. Survival curves of the three A-stages ran close together with median survival times of 58, 51, and 36 months. Only the A-B classification according to renal function (A: creatinine under 2 mg/dl; B: creatinine above 2 mg/dl) proved prognostically relevant.

Entities:  

Mesh:

Year:  1984        PMID: 6503212     DOI: 10.1007/bf01727438

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  55 in total

1.  Growth rates and responses to treatment in human myelomatosis.

Authors:  J R Hobbs
Journal:  Br J Haematol       Date:  1969-06       Impact factor: 6.998

2.  Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.

Authors:  Y Matzner; J Benbassat; A Polliack
Journal:  Isr J Med Sci       Date:  1977-08

3.  Letter: Variety in general practice.

Authors:  P Jacobs; D Dubovsky; H S King
Journal:  S Afr Med J       Date:  1975-04-12

4.  Smoldering multiple myeloma.

Authors:  R A Kyle; P R Greipp
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

5.  Bone marrow percentage of plasma cells in the staging of monoclonal gammopathies.

Authors:  D Vercelli; R Di Guglielmo; G Guidi; L Scolari; L Buricchi; F Cozzolino
Journal:  Nouv Rev Fr Hematol       Date:  1980

6.  Monitoring myelomatosis.

Authors:  J R Hobbs
Journal:  Arch Intern Med       Date:  1975-01

7.  Correlation of abnormal immunoglobulin with clinical features of myeloma.

Authors: 
Journal:  Arch Intern Med       Date:  1975-01

8.  Prognostic factors in multiple myeloma.

Authors:  R Alexanian; S Balcerzak; J D Bonnet; E A Gehan; A Haut; J S Hewlett; R W Monto
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

9.  Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.

Authors:  V Hofmann; S E Salmon; B G Durie
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

10.  Clinical staging in multiple myeloma.

Authors:  R K Woodruff; J Wadsworth; J S Malpas; J S Tobias
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

View more
  2 in total

1.  [Fulminating course of IgG plasmacytoma at a young age].

Authors:  C Görg; H P Sinn; K Görg; K Havemann
Journal:  Klin Wochenschr       Date:  1986-04-01

2.  Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.

Authors:  H Diem; A Fateh-Moghadam; R Lamerz
Journal:  Clin Investig       Date:  1993-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.